Biogen’s Zurzuvae Strategy Shifts as OB/GYNs Rise to the Front Lines Nearly two years in with Zurzuvae, Biogen tackles an ‘all of the above market’ to find patients and battle stigma in postpartum depression.

www.biospace.com/business/bio...
@dynavox.bsky.social
Prescribing trend changes with #Zurzuvae for #PostpartumDepression (from May)

First Pill for Postpartum Depression Shows Varied Real-World Results

www.nytimes.com/2025/07/22/h...
@thenewslizard.bsky.social
@dynavox.bsky.social
Sorry for no unlocks left, mixed results on #Zurzuvae for #PostpartumDepression.
60% success rate, many others reported the sedating effect is just not manageable.

In a field where men are the default and female aspects under-researched, it’s no surprise that postpartum depression—happening to 1 in 7 women—hasn’t been treatable with a simple pill. Until now. Progress happens. #FeministFriday #GenderEquality #PPD #zuranolone #zurzuvae #research